Repeated scandals, an attitude that is suspected as concealment and a lack of succession planning at Toho HD indicate its serious breakdown in corporate governance The Board of Directors continues to reject reasonable proposals for operational improvement, obstructing the Company’s path to sustainable value creation The persistent failure to address compliance issues risks alienating its … [Read more…]

MARSEILLE, France–(BUSINESS WIRE)–#IRConferences–Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team will present and host 1×1 meetings at the upcoming investor conferences, detailed below. Jefferies Global Healthcare Conference Dates: June 3 – 5 2025 | New York, USA The executive team will … [Read more…]

Fund close exceeds initial target despite a challenging fundraising environment, reflecting strong investor confidence in India and Southeast Asia healthcare Existing investors increased commitment amount by an average of 80% New capital raised from blue-chip global institutions, alongside a significant rise in Asian investor participation HO CHI MINH CITY, Vietnam–(BUSINESS WIRE)–Quadria Capital, Asia’s premier healthcare-focused … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Digital Therapeutics Market – A Global and Regional Analysis: Focus on Product Type, Application, Sales Channel, and Country – Analysis and Forecast, 2025-2035” report has been added to ResearchAndMarkets.com’s offering. The global digital therapeutics market includes clinically validated software and devices that are evidence-based. These tools are intended for the treatment of a … [Read more…]

PXL065 demonstrated significant benefits in a HCM mouse model preventing pathological myocardial remodeling, including hypertrophy and fibrosis in the heart Presentation of detailed results from preclinical study on Sept 1st, 2025, 11:15 am CEST, at the European Society of Cardiology 2025 Findings support the clinical development of PXL065 as a potential disease- modifying treatment for … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “VISTA Inhibitor Clinical Trials, Drug Development Opportunities & Patent Insight 2025” report has been added to ResearchAndMarkets.com’s offering. The landscape of cancer immunotherapy has witnessed remarkable transformations in recent years, with immune checkpoint inhibitors revolutionizing treatment approaches for various malignancies. With the massive success of first generation immune checkpoint inhibitors, such as pembrolizumab … [Read more…]

Industry-leading debut of Canada’s most advanced health and wellness model that combines advanced health diagnostics with a premium fitness and recovery membership experience. TORONTO–(BUSINESS WIRE)–In a bold move set to reshape Canada’s health and wellness landscape, Stride — the digital-first leader in health optimisation — has partnered with UNITY Fitness Harbourfront, Toronto’s destination for holistic … [Read more…]

BRENTWOOD, Tenn.–(BUSINESS WIRE)–Ardent Health Partners, Inc. (NYSE: ARDT) (“Ardent Health” or the “Company”), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that its board of directors voted to change the Company’s name to Ardent Health, Inc., effective June 3, 2025. The updated name aligns the Company’s legal name … [Read more…]

BOSTON–(BUSINESS WIRE)–Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced that it has expanded its immunohistochemistry (IHC) test offerings to include MET IHC testing using the VENTANA® MET (SP44) RxDx assay, now available as an add-on to comprehensive genomic profiling (CGP) test orders for patients with non-squamous non-small cell lung cancer … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Epigenetics Market” report has been added to ResearchAndMarkets.com’s offering. The global market for epigenetics research tools and reagents, IVDs and therapeutics is expected to grow from $4.8 billion in 2024 to $8.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.8% from 2024 through 2029. This report … [Read more…]